Robust 4Q 2014 Life Science Sales Index Growth

摘要

Fourth quarter 2014 IBO Life Science Index sales grew 7.3%, 9.0% organically, to $4,317 million, marking its strongest organic growth since the first quarter of 2010. Growth was driven by demand from US pharmaceutical and biotechnology customers, increased research spending in Europe and positive demand in China. However, delayed spending in Japan and weak academic sales in Europe negatively impacted other companies. Adjusted operating profit climbed 9.0% to $1,058 million due to strong results from Illumina. Operating margin expanded 50 basis points to 21.3% of sales. Excluding Illumina, Index sales grew 5.8% organically and adjusted operating profit was flat.